Axxam and HeartBeat.bio Form Partnership for Cardiovascular Drug Innovation

Axxam, a key player in drug discovery services, has joined forces with HeartBeat.bio, a leader in human cardiac organoid technology. This strategic alliance aims to enhance cardiovascular drug discovery and cardiac safety assessment. Based in Milan and Vienna, the two companies will combine their respective strengths to provide next-level, human-relevant solutions.

Axxam contributes its extensive expertise in drug discovery processes, including target validation, assay development, and ADME profiling. Meanwhile, HeartBeat.bio offers its proprietary 3D human cardiac organoid platform, designed to emulate essential human heart tissue features for accurate disease modeling and safety evaluations.

Representatives from both companies emphasized the partnership’s potential to improve decision-making and reduce development risks. Michael Krebs of HeartBeat.bio highlighted the industry's growing demand for predictive models, enhancing preclinical to clinical translation. This partnership is part of a broader industry trend embracing New Approach Methodologies to increase clinical success rates.